HC Wainwright reissued their buy rating on shares of Arcadia Biosciences (NASDAQ:RKDA – Free Report) in a report issued on Wednesday, Benzinga reports. HC Wainwright currently has a $6.00 price target on the basic materials company’s stock. HC Wainwright also issued estimates for Arcadia Biosciences’ Q3 2024 earnings at ($0.77) EPS, Q4 2024 earnings at ($0.50) EPS, FY2024 earnings at ($1.70) EPS, Q1 2025 earnings at ($0.37) EPS, Q2 2025 earnings at $0.66 EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.09) EPS and FY2025 earnings at $0.12 EPS.
RKDA has been the subject of a number of other research reports. StockNews.com initiated coverage on shares of Arcadia Biosciences in a report on Monday, August 19th. They issued a sell rating for the company. Lake Street Capital upgraded shares of Arcadia Biosciences to a strong-buy rating in a report on Tuesday, May 14th.
View Our Latest Report on RKDA
Arcadia Biosciences Price Performance
Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The basic materials company reported $0.78 earnings per share for the quarter, missing the consensus estimate of $1.27 by ($0.49). The firm had revenue of $1.31 million for the quarter, compared to analyst estimates of $0.95 million. Arcadia Biosciences had a negative net margin of 127.29% and a negative return on equity of 57.51%. During the same period last year, the business earned ($2.64) EPS. As a group, analysts expect that Arcadia Biosciences will post -2.29 EPS for the current year.
Arcadia Biosciences Company Profile
Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.
Featured Articles
- Five stocks we like better than Arcadia Biosciences
- 3 REITs to Buy and Hold for the Long Term
- Lumen: Among Top Performers Last Month, Still Has Warning Signs
- How to Use Stock Screeners to Find Stocks
- Baidu’s Strong Quarter Proves a Smart Pick for Michael Burry
- How to Invest in the FAANG Stocks
- Intuit Beats Q4 Earnings: AI, Dividends, and a Growth Strategy
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.